HSTO vs. BLPH, CMRA, EVFM, SXTC, SPRC, APVO, ADTX, EVLO, SBFM, and ATHX
Should you be buying Histogen stock or one of its competitors? The main competitors of Histogen include Bellerophon Therapeutics (BLPH), Comera Life Sciences (CMRA), Evofem Biosciences (EVFM), China SXT Pharmaceuticals (SXTC), SciSparc (SPRC), Aptevo Therapeutics (APVO), Aditxt (ADTX), Evelo Biosciences (EVLO), Sunshine Biopharma (SBFM), and Athersys (ATHX). These companies are all part of the "pharmaceutical preparations" industry.
Histogen (NASDAQ:HSTO) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, community ranking, earnings, dividends, media sentiment, risk and analyst recommendations.
Histogen has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Bellerophon Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.
In the previous week, Bellerophon Therapeutics had 1 more articles in the media than Histogen. MarketBeat recorded 1 mentions for Bellerophon Therapeutics and 0 mentions for Histogen. Histogen's average media sentiment score of 0.00 equaled Bellerophon Therapeutics'average media sentiment score.
Bellerophon Therapeutics has a net margin of 0.00% compared to Histogen's net margin of -65,142.11%. Histogen's return on equity of -136.13% beat Bellerophon Therapeutics' return on equity.
Histogen has higher revenue and earnings than Bellerophon Therapeutics. Histogen is trading at a lower price-to-earnings ratio than Bellerophon Therapeutics, indicating that it is currently the more affordable of the two stocks.
Bellerophon Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 3,452.40%. Given Bellerophon Therapeutics' higher possible upside, analysts clearly believe Bellerophon Therapeutics is more favorable than Histogen.
10.6% of Bellerophon Therapeutics shares are owned by institutional investors. 3.3% of Histogen shares are owned by insiders. Comparatively, 5.2% of Bellerophon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Bellerophon Therapeutics received 312 more outperform votes than Histogen when rated by MarketBeat users. Likewise, 60.42% of users gave Bellerophon Therapeutics an outperform vote while only 58.33% of users gave Histogen an outperform vote.
Summary
Bellerophon Therapeutics beats Histogen on 9 of the 14 factors compared between the two stocks.
Get Histogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Histogen Competitors List
Related Companies and Tools
